Loading...
•
Jun 30, 2023
MannKind Q2 2023 Earnings Report
Reported positive income from operations driven by growing patient demand for Tyvaso DPI® and Afrezza as well as manufacturing revenues from Tyvaso DPI.
Key Takeaways
MannKind Corporation reported a significant increase in total revenues for Q2 2023, driven by growth in Tyvaso DPI royalties and Afrezza net revenues, along with revenues from collaborations and services. The company achieved positive income from operations during the quarter.
Total revenues increased by 157% compared to Q2 2022, reaching $49 million.
Tyvaso DPI royalties grew by 63% compared to Q1 2023, totaling $19 million.
Endocrine Business Unit net revenues were $18 million, with Afrezza net revenues increasing by 27% compared to Q2 2022.
The company reported income from operations of $2 million and non-GAAP income from operations of $8 million.
Revenue by Segment
Forward Guidance
MannKind expects the optimization of commercial operations supporting Afrezza and V-Go, which is expected to get our Endocrine Business Unit to profitability starting in 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...